Trial Profile
An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For Pain Associated With Diabetic Peripheral Neuropathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Diabetic neuropathies; Neurogenic pain
- Focus Adverse reactions
- Sponsors Pfizer
- 20 Sep 2018 New trial record
- 21 Feb 2008 Status changed from not yet recruiting to recruiting.